P53 and Chemosensitivity in Bladder Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2008 Aug 16

PMID 18704627

Citations 12

Authors

Hiroyuki Nishiyama

Jun Watanabe

Osamu Ogawa

Affiliations

Soon will be listed here.

Abstract

Urothelial carcinoma is the second most common genitourinary malignancy. Although the majority of patients present with superficial bladder tumors, there are several clinical problems, such as progression to invasive tumors, poor prognosis of invasive tumors, and chemosensitivity. Alterations in p53 represent one of the most common genetic events in patients with invasive urothelial carcinoma and are suggested to be linked to tumor progression, prognosis, and chemosensitivity. p53 possesses various functions, including induction of cell-cycle arrest, apoptosis, DNA repair, and antioxidants; it acts as a killer and a healer. In this article, we review the roles of p53 pathways in bladder carcinogenesis and findings from recent studies of ours and other groups, and we discuss the clinical significance of the abrogation of p53 pathways in the treatment of urothelial carcinoma.

Citing Articles

Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs.

Zhao J, Zhang Q, Zhu C, Yuqi W, Zhang G, Wang Q BioData Min. 2024; 17(1):59.

PMID: 39695796 PMC: 11657289. DOI: 10.1186/s13040-024-00377-x.

Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.

Ren C, Wang Q, Xu Z, Pan Y, Li Y, Liu X J Cancer Res Clin Oncol. 2023; 149(17):15805-15818.

PMID: 37668798 DOI: 10.1007/s00432-023-05352-3.

A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome.

Une M, Fujiwara R, Ueki A, Oki R, Urasaki T, Inamura K IJU Case Rep. 2023; 6(5):286-289.

PMID: 37667764 PMC: 10475342. DOI: 10.1002/iju5.12607.

Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.

Alradhi M, Wen S, Safi M, Al-Danakh A, Wang H, Shopit A Cancer Med. 2023; 12(4):3931-3951.

PMID: 36779496 PMC: 9972163. DOI: 10.1002/cam4.5121.

Fruit Extract Induces Tp53/Caspase-Mediated Apoptosis in MCF-7 Breast Cancer Cells.

Alshammari G, Balakrishnan A, Alshatwi A, Al-Khalifa A Biomed Res Int. 2020; 2020:3712536.

PMID: 32685475 PMC: 7335397. DOI: 10.1155/2020/3712536.

References

Martinez L, Yang J, Vazquez E, Olive M, Hsieh J, Logothetis C . p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002; 23(8):1289-96. DOI: 10.1093/carcin/23.8.1289. View

Stein J, Grossfeld G, Ginsberg D, Esrig D, Freeman J, Figueroa A . Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998; 160(3 Pt 1):645-59. DOI: 10.1016/S0022-5347(01)62747-2. View

Mitra A, Birkhahn M, Cote R . p53 and retinoblastoma pathways in bladder cancer. World J Urol. 2007; 25(6):563-71. DOI: 10.1007/s00345-007-0197-0. View

Olivier M, Eeles R, Hollstein M, Khan M, Harris C, Hainaut P . The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19(6):607-14. DOI: 10.1002/humu.10081. View

Bakkar A, Wallerand H, Radvanyi F, Lahaye J, Pissard S, Lecerf L . FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003; 63(23):8108-12. View

Cheng W, Zheng X, Quimby F, Roneker C, Lei X . Low levels of glutathione peroxidase 1 activity in selenium-deficient mouse liver affect c-Jun N-terminal kinase activation and p53 phosphorylation on Ser-15 in pro-oxidant-induced aponecrosis. Biochem J. 2002; 370(Pt 3):927-34. PMC: 1223242. DOI: 10.1042/BJ20021870. View

Matsui Y, Ueda S, Watanabe J, Kuwabara I, Ogawa O, Nishiyama H . Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res. 2007; 67(3):1212-20. DOI: 10.1158/0008-5472.CAN-06-3283. View

Olive K, Tuveson D, Ruhe Z, Yin B, Willis N, Bronson R . Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119(6):847-60. DOI: 10.1016/j.cell.2004.11.004. View

Sablina A, Budanov A, Ilyinskaya G, Agapova L, Kravchenko J, Chumakov P . The antioxidant function of the p53 tumor suppressor. Nat Med. 2005; 11(12):1306-13. PMC: 2637821. DOI: 10.1038/nm1320. View

10.

Menendez D, Inga A, Jordan J, Resnick M . Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Oncogene. 2007; 26(15):2191-201. DOI: 10.1038/sj.onc.1210277. View

11.

Shariat S, Zlotta A, Ashfaq R, Sagalowsky A, Lotan Y . Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007; 20(4):445-59. DOI: 10.1038/modpathol.3800757. View

12.

Qureshi K, Griffiths T, Robinson M, Marsh C, Roberts J, Hall R . TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res. 1999; 5(11):3500-7. View

13.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

14.

Mitra A, Datar R, Cote R . Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006; 24(35):5552-64. DOI: 10.1200/JCO.2006.08.2073. View

15.

Soussi T . p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000; 60(7):1777-88. View

16.

Weiss R, Marshall D, Howard L, Corbacho A, Cheung A, Sawai E . Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). Cancer Lett. 2002; 189(1):39-48. DOI: 10.1016/s0304-3835(02)00495-0. View

17.

Watanabe J, Nishiyama H, Okubo K, Takahashi T, Toda Y, Habuchi T . Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology. 2004; 63(5):989-93. DOI: 10.1016/j.urology.2003.11.031. View

18.

Livingstone L, White A, Sprouse J, Livanos E, Jacks T, Tlsty T . Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 1992; 70(6):923-35. DOI: 10.1016/0092-8674(92)90243-6. View

19.

Okuda E, Osugi H, Morimura K, Takada N, Takemura M, Fukushima S . Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group. Clin Cancer Res. 2001; 7(3):600-6. View

20.

Weller M . Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998; 292(3):435-45. DOI: 10.1007/s004410051072. View